Asthma Symposium Agenda v.5 2013

8/13/2019 Asthma Symposium Agenda v.5 2013

1/5

www.allergen-nce.ca

2nd International Symposium on the Economics of Asthma and Asthma Ca

A Free Pre-Congress Symposium to the 9th

World Congress on Health Economics

Sydney, Australia, Saturday July 6, 2013Sydney Convention and Exhibition Centre, Darling Harbour, Bayside 204B

Key Presenters

Larry Lynd, PhD, BSP, University of British Columbia and AllerGen Networks of

Centres of Excellence (NCE), Canada

Larry Lynd is Associate Professor and Associate Director of the Collaboration for

Outcomes Research and Evaluation in the Faculty of Pharmaceutical Sciences, an

Associate in the School of Population and Public Health, and a Scientist at the Cent

for Health Evaluation and Outcomes Sciences at the University of British Columbia.

He is the Co-PI of the AllerGen Networks of Centres of Excellence Platform for

Outcomes Research and Translation in Asthma and Allergy (PORTAL), and he is the

principal investigator of a CIHR New Emerging Team Grant for Rare Diseases. He is

also a member of the Health Canada Special Advisory Committee for Respiratory a

Allergy Therapies. His primary research interests involve benefit-risk analysis,

pharmaco-epidemiology and health outcomes research, and health policy related to orphan drugs.

Dr. Richard Loh, University of Western Australia, Perth, Australia

Associate Professor Richard Loh is the Head of the Immunology Department at

Princess Margaret Hospital and Clinical Associate Professor at the University of

Western Australia. Richard is a graduate of the University of Queensland and trainin Immunology and Allergy at the Children's Hospital in Boston and Harvard Medic

School. He is the President of ASCIA and a member of the AAAAI Anaphylaxis

Committee. He is actively involved in anaphylaxis management and chaired the

ASCIA Anaphylaxis Working Party for 4 years during which time they developed

online anaphylaxis training. Richard is the Chair of the Anaphylaxis Expert

Committee which is developing an anaphylaxis model of care in Western Australia, as well as a member of t

WA Anaphylaxis Project Advisory Group.


2/5

www.allergen-nce.ca

Dr. Mohsen Sadatsafavi , MD, PhD, Department of Medicine, University of Briti

Columbia (UBC) & AllerGen NCE, Canada

Mohsen Sadatsafavi is an Assistant Professor of Health Economics and Outcomes

Research at the Division of Respiratory Medicine, Department of Medicine,

University of British Columbia. He is also a scientist at the Centre for Clinical

Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, and i

an affiliate in the Collaboration for Outcomes Research and Evaluation at UBC. D

Sadatsafavi's program of research encompasses three components of clinical

studies, analysis of administrative health databases, and decision-analytic

modeling of chronic respiratory conditions. Since starting his academic

appointment at UBC in July 2012, he has been involved in several studies,

including: the comparative effectiveness of competing treatments for asthma; measuring the preventable

productivity loss in asthma; impact of the specialty of care on long-term outcomes in asthma and COPD; the

humanistic and economic benefit of following asthma treatment guidelines, and; benefit risk analysis of

various screening strategies for latent tuberculosis infection.

Dr. Wendy Ungar, PhD, MSc,Hospital for Sick Children, University of Toronto and

AllerGen NCE, Canada

Wendy Ungar is a Senior Scientist in Child Health Evaluative Sciences at The Hospita

for Sick Children, Toronto, Canada, an Associate Professor in Health Policy,

Management and Evaluation, University of Toronto, and an Adjunct Scientist at the

Institute for Clinical Evaluative Sciences. Dr. Ungar leads a program of research in th

application of health economic methods to the paediatric population and also

investigates the relationship between policies governing access to prescription

medicines and health outcomes in children with asthma. Dr. Ungar directs TASK

(Technology Assessment at The Hospital for Sick Children), a health technology

assessment research unit focusing on technology assessment of pediatric health

interventions. In 2010, Dr. Ungars book,Economic Evaluation in Child Health, was published by Oxford

University Press.


3/5

www.allergen-nce.ca

SATURDAY, JULY 6, 2013

8:30AM REGISTRATION AND LIGHT BREAKFAST Bayside 204B

9:159:30AM WELCOME AND OPENING REMARKS Bayside 204B

Diana Royce, EdD, Managing Director and COO, AllerGen NCE Inc., Canada

9:3010:30AMOPENING KEYNOTE PRESENTATION:WHERE DO WE STAND IN THE

ECONOMICS OF ASTHMA AND ASTHMA CARE?Bayside 204B

Larry Lynd, PhD, University of British Columbia and AllerGen NCE, Canada

The introduction of inhalers 50 years ago, and in particular salbutamol and

beclomethasone, radically changed the treatment of asthma. For decades,

however, there was little advancement in treatment options. Today, the

advent of biologics, personalized medicine and bronchial thermoplasty offer

new possibilities for the effective, targeted diagnosis and treatment options

of asthma.

This session will provide an overview of the economic implications of thecurrent state of asthma and asthma care as it relates to the current drug

pipeline, new treatments and the continuing challenge of treatment

adherence.

10:3011:00AM BREAK

11:0012:15PMWHAT DO WE REALLY KNOW ABOUT THE ECONOMIC COST OF

ASTHMA?Bayside 204B

Mohsen Sadatsafavi, MD, PhD, University of British Columbia & AllerGen NCE,

Canada

Analysis of Asthma and Asthma Care Costs from a Canadian Perspective

Ning Yan Gu, PhD, University of New Mexico, USA

Predicting Healthcare Costs in Asthma using the EQ-5D Health-Related Quality-of-

Life Index Score

12:151:00PM NETWORKING LUNCH

1:001:45PMLUNCH KEYNOTE PRESENTATION:NATIONAL ANAPHYLAXIS

STRATEGY IN AUSTRALIA -LESSONS FOR ASTHMABayside 204B

Dr. Richard Loh, University of Western Australia, Perth, Australia

Dr. Loh was instrumental in developing a successful Anaphylaxis

Strategy in Western Australia that has helped meet the challenges of

severe life-threatening allergy head-on. Dr. Loh will offer thoughts on

how to apply this successful program to asthma.


4/5

www.allergen-nce.ca

1:452:30PM INTERACTIVE SESSION:BUILDING A NATIONAL ASTHMA STRATEGY Bayside 204B

This session is designed to allow both presenters and the audience a

chance to discuss how to take lessons from the Australian

Anaphylaxis Strategy and apply them to the development of a

workable national asthma strategy:

What are the 3-5 most important lessons from the Australian

Anaphylaxis Strategy?

What specific features/foci are essential to the development

of a national asthma strategy?

What country-specific, culture-specific barriers need to be

overcome?

How should stakeholder groups including patients,

academics, industry and policy makers be involved in the

implementation of a national asthma strategy and what role

should they play?

Chair: Diana Royce, EdD, Managing Director and COO, AllerGen NCE,

Canada

2:303:00PM BREAK

3:004:15PM UNDERSTANDING ASTHMA CONTROL Bayside 204B

Lilla Roy, MSc Student, University of British Columbia, Canada and AllerGen NCE, Canada

Evaluating preferences for long term wheeze following RSV infection using TTO and

Best-Worst Scaling

Wendy Ungar, PhD, MSc, Hospital for Sick Children, University of Toronto and AllerGen

NCE, Canada

Achieving Asthma Control in Children: What Do Parents and Adolescents think is

Important?

4:154:30PM NEXT STEPS AND CLOSING REMARKS Bayside 204B

Diana Royce, EdD, Managing Director and COO, AllerGen NCE , Canada

Bill Swan,Deputy CEO, International Health Economics Association, Nova Scotia, Canada


5/5

www.allergen-nce.ca

Organizing Committee:

Chair:

Dr. Diana Royce, EdD, AllerGen NCE, Canada

Members:

Dr. Mohsen Sadatsafavi, MD, PhD, University of British Columbia & AllerGen NCE, Canada

Bill Swan, Deputy CEO, International Health Economics Association; Chair, National Asthma Patient Alliance;

Board Member, Asthma Society of Canada, Member, Health Canada Special Advisory Committee for

Respiratory and Allergy Therapies, Nova Scotia, Canada

Dr. Wendy Ungar, PhD, MSc, Hospital for Sick Children, University of Toronto & AllerGen NCE, Canada

Dr. Carlo Marra, PharmD, PhD, Associate Professor & Director, CORE | Faculty of Pharmaceutical Sciences,

University of British Columbia & AllerGen NCE, Canada

AllerGen NCE Inc.,the Allergy, Genes and Environment Network, (est. 2004), is a national research

network funded by Industry Canada through the Networks of Centres of Excellence (NCE) Program.

AllerGens mandate is to support research, networking, commercialization, knowledge mobilization andcapacity building activities that contribute to reducing the morbidity, mortality and socio-economic

impacts of asthma, allergy and anaphylaxis.

www.allergen-nce.ca
http://www.allergen-nce.ca/http://www.allergen-nce.ca/http://www.allergen-nce.ca/

Asthma Symposium Agenda v.5 2013

Documents

Transcript of Asthma Symposium Agenda v.5 2013